艾伯维公司以最新突破性研究形式,在2026年EADV大会上公布了Zumilokibart用于中重度特应性皮炎的II期APEX B部分研究取得的积极结果。
艾伯维公司以最新突破性研究形式,在2026年EADV大会上公布了Zumilokibart用于中重度特应性皮炎的II期APEX B部分研究取得的积极结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.